

## **LIFECARE CONFIRMS 12-WEEK IMPLANT STABILITY UNDER REAL-LIFE CONDITIONS – MATERIALLY REDUCES DURABILITY RISK AHEAD OF FIRST-IN-HUMAN STUDY**

**Bergen, Norway, 5 March 2026 – Lifecare ASA (LIFE), a MedTech company developing next-generation implantable Continuous Glucose Monitoring (CGM) technology, today announces a significant durability milestone in its ongoing longevity study.**

Following the Q4 2025 report, which marked the transition from proof-of-concept to system-level validation, Lifecare now reports stable implant performance beyond 12 weeks of implantation. No structural signal degradation has been observed.

12 weeks of stable real-life performance represents a meaningful step toward Lifecare's ambition of long-term, calibration-free implantable glucose monitoring.

### **12 weeks completed within six-month framework**

In October 2025, Lifecare received regulatory approval permitting implantation in dogs for up to six months, extending the previous three-month allowance. The first study cohort completed the planned three-month evaluation confirming safety and biocompatibility. The second cohort is initiated under the expanded six-month framework and the first 12 weeks of continuous implantation have now been successfully completed.

This milestone extends the demonstrated operational window of the implant within a six-month implantation horizon.

### **Stable performance in real-life conditions**

The animals live as home-dogs outside the clinic under normal activity and environmental exposure. The data confirms consistent signal generation, preserved dynamics, reliable wireless communication, and no noise escalation or signal collapse under these real-life conditions.

An important characteristic of long-term implantable systems is controlled and predictable signal behaviour. This enables precise modelling and algorithmic optimisation and supports sustained performance over extended implantation periods.

Lifecare's implant demonstrates stable signal behaviour over time, with gradual and predictable drift consistent with expected electrochemical ageing.

This reinforces the durability of the technology and underlines its readiness for the next phase of development.

### **Progression toward first-in-human**

As previously communicated, the electronics module has achieved CE marking and ethics approval for first-in-human (FIH) studies is in place, with regulatory clearance pending. The extended longitudinal data further strengthens system robustness ahead of human trials. Demonstrating stable signal behaviour over 12 weeks in real-life settings is a key prerequisite for progressing implantable sensor systems toward human clinical use.

“The key question for any implantable sensor is not only whether it works initially, but whether it behaves predictably over time,” says Joacim Holter, CEO of Lifecare. “Stable performance beyond 12 weeks in real-life physiological conditions materially reduces durability risk and supports our progression toward human studies.”

### **Outlook**

The longevity study continues toward the six-month evaluation window. Signal optimisation and reference benchmarking remain ongoing.

### **About us**

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

### **Contacts**

For further information, please contact:

Joacim Holter, CEO, [joacim.holter@lifecare.no](mailto:joacim.holter@lifecare.no), +47 40 05 90 40

Renete Kaarvik, CFO, [renete.kaarvik@lifecare.no](mailto:renete.kaarvik@lifecare.no), +47 94 83 82 42